Crowdonomics
REGENMED

Reg CF · Class B Non-Voting Shares · Jun 2025

WithdrawnReg CFCommon Equity
via DealMaker · last checked Sep 25, 2026
Raised
$0 / $4.7M max
0% of ceiling
Investors
—
—
Post-money valuation
$25M
pre-money + amount raised

Financials disclosed in this offering

FY2023–FY2024 · hover for source
$97K
−$1.1M
FY2023
$281K
−$1.1M
FY2024
RevenueNet income
Metric
FY2023 reviewed
FY2024 unaudited
Income statement
Revenue
$96,500
$280,793
Cost of goods sold
$0
$25,000
Gross margin
100%
91%
Net income
-$1,093,806
-$1,075,117
Taxes paid
$0
$0
Balance sheet
Cash
$60,817
$36,268
Accounts receivable
$0
$0
Total assets
$1,265,684
$780,046
Short-term debt
$0
$0
Long-term debt
$1,615,000
$0
Total liabilities
$1,615,000
$0
Other
Headcount
1
14

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

1 amendment
  1. Jun 16, 2025
    No change to filed terms

    “This non-material amendment is being filed to correct a typographical error showing "Draft" for Exhibit A to the Offering Statement.”

    Form C/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. The quoted reason is the issuer’s own statement from the Form C/A.

Deal terms

Pre-money$25M
Post-money$25M
Price / share$12.00
Shares offered1,208

Offering details

Target$15,003
Max$4,741,509
Min investment—
OpenedJun 13, 2025
DeadlineDec 31, 2025
ClosedJan 29, 2026
Days active230

Links & provenance

Source: SEC EDGAR
0001062993-25-011594
Last synced Sep 25, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.